Prestige Biopharma said Monday it would build a vaccine production center for Covid-19 and other infectious diseases.
The antibody-drug developer said it would break grounds for the vaccine center with the floor space of about 8,500 square meters separate from its second plant for antibody-drug production pushed by Prestige BioLogics.
When completed, the vaccine center will have up to 100,000 liters' production capacity and proactively respond to manufacturing various infectious diseases, including the Covid-19 vaccine, the company said. Construction will begin this month and end by the end of this year.
“The prolonged Covid-19 pandemic is increasing concerns about virus infections in the future while raising expectations about related vaccines,” Prestige Bio CEO Park So-yeon, said. “We expect to contribute to preventing future pandemics while securing a new engine for making profits.”